EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of an alternative dosing schedule for its PD‑1 inhibitor Libtayo (cemiplimab) across all approved indications. The recommendation supports both an extended every‑six‑week, 700 mg regimen and a 15‑ to 30‑minute infusion option that could cut treatment time by up to half – a meaningful convenience advance for patients receiving the immunotherapy in Europe, pending a final European Commission (EC) decision.

Regulatory Milestone

Dosing Flexibility – What the CHMP Recommended

• Extended Every‑Six‑Week Regimen: Libtayo 700 mg administered as a 30‑minute intravenous infusion every six weeks (Q6W), following an initial 12‑week regimen of Libtayo 350 mg given as a 30‑minute IV infusion every three weeks (Q3W) – halving clinic visit frequency after the induction period.
• Shortened Infusion Option: For patients receiving Libtayo 350 mg Q3W, a 15‑ to 30‑minute infusion option is supported if their first infusion at this dose level was well tolerated when administered over 30 minutes – potentially cutting treatment time by up to half.
• Label‑Wide Application: The alternative schedules apply across all approved indications, standardizing convenience benefits throughout the Libtayo franchise rather than limiting them to a single tumor type.

Drug Profile & Mechanism of Action

• Molecule: Cemiplimab (Libtayo) – a fully human monoclonal antibody.
• Target: The immune checkpoint receptor PD‑1 on T cells.
• Mechanism: By binding to PD‑1, Libtayo has been shown to block cancer cells from using the PD‑1 pathway to suppress T‑cell activation, restoring anti‑tumor immune responses.
• Discovery Platform: Invented using Regeneron’s proprietary VelocImmune technology, the company’s fully‑human antibody discovery platform.
• Global Footprint: Approved by regulatory authorities in more than 30 countries.

Approved Indications

Libtayo is currently approved for certain adult patients with:

• Advanced basal cell carcinoma (BCC)
• Advanced or high‑recurrence‑risk cutaneous squamous cell carcinoma (CSCC)
• Advanced non‑small cell lung cancer (NSCLC)
• Advanced cervical cancer

Market Impact & Outlook

• Patient Convenience as Differentiator: Q6W dosing and 15‑minute infusion options reduce chair time and clinic visits – an increasingly decisive factor as PD‑1 competition intensifies across advanced solid tumors.
• Franchise‑Wide Label Upgrade: Because the flexibility extends across all approved indications, the dosing change benefits BCC, CSCC, NSCLC and cervical cancer patients alike, supporting retention and adoption in every commercial segment.
• European Conversion Watch: CHMP positive opinions are typically adopted by the European Commission within a short procedural window; the final EC decision will formalize the label change (timeline not disclosed).
• Global Parallel Potential: Investors will watch for corresponding FDA and other regional label updates on extended dosing and shorter infusion times (none announced).

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the recommended alternative dosing schedule for Libtayo (cemiplimab), the anticipated European Commission decision, and potential label updates in other regions. Actual results may differ materially due to risks including the EC review process, clinical experience with extended dosing intervals, competitive dynamics in PD‑1 immunotherapy, and pricing and reimbursement conditions. A CHMP positive opinion does not guarantee final marketing authorisation.-Fineline Info & Tech